cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model西洛地唑激活函数在一个骨骨髓来源的内皮祖细胞的再内皮化颈动脉球囊损伤模型.pdfVIP

Cilostazol Activates Function of Bone Marrow-Derived Endothelial Progenitor Cell for Re-endothelialization in a Carotid Balloon Injury Model 1,2 3,1 2 1,4 2 Rie Kawabe-Yako , Masaaki Ii *, Osamu Masuo , Takayuki Asahara *, Toru Itakura 1 Group of Vascular Regeneration Research, Institute of Biomedical Research and Innovation, RIKEN Center for Developmental Biology, Kobe, Japan, 2 Department of Neurosurgery, Wakayama Medical University, Wakayama, Japan, 3 Group of Translational Stem Cell Research, Department of Pharmacology, Osaka Medical College, Osaka, Japan, 4 Department of Regenerative Medicine Science, Tokai University School of Medicine Kanagawa, Japan Abstract Background: Cilostazol(CLZ) has been used as a vasodilating anti-platelet drug clinically and demonstrated to inhibit proliferation of smooth muscle cells and effect on endothelial cells. However, the effect of CLZ on re-endothelialization including bone marrow (BM)-derived endothelial progenitor cell (EPC) contribution is unclear. We have investigated the hypothesis that CLZ might accelerate re-endothelialization with EPCs. Methodology/Principal Findings: Balloon carotid denudation was performed in male Sprague-Dawley rats. CLZ group was given CLZ mixed feed from 2weeks before carotid injury. Control group was fed normal diet. CLZ accelerated re- endothelialization at 2 weeks after surgery and resulted in a significant reduction of neointima formation 4 weeks after surgery compared with that in control group. CLZ also increased the number of circulating EPCs throughout the time course. We examined the contribution of BM-derived EPCs to re-endoth